医学
慢性鼻-鼻窦炎
鼻息肉
美波利祖马布
鼻窦炎
胃肠病学
内科学
外科
嗜酸性粒细胞
哮喘
作者
Mehmet Erdem Cakmak,Osman Ozan Yeğit
标识
DOI:10.5114/pja.2023.125768
摘要
Introduction: The anti-interleukin (IL)-5 antibody mepolizumab has been used in the treatment of patients with uncontrolled severe eosinophilic asthma.Aim: In this real-life study, we aimed to evaluate the effect of mepolizumab on nasal symptoms in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).Material and methods: Adult patients (> 18 years old) with concomitant CRSwNP, who were treated with mepolizumab at a dose of 100 mg every 4 weeks for at least one year for severe eosinophilic asthma, between 2021 and 2022, were evaluated retrospectively.Asthma control testing (ACT), Sino-Nasal Outcome Test (SNOT-22), and a visual analogue scale (VAS) of 1 to 10 (from 1 to 10) for nasal symptoms were compared at baseline (pre-mepolizumab treatment), and at 6 and 12 months post-treatment.The need for endoscopic sinus surgery (ESS) and oral corticosteroid (OCS) was compared at 12 months pre-mepolizumab and post-mepolizumab treatment.Results: The mean age of the 18 patients (9 (50%) males and 9 (50%) females) was 42.33 ±15.9 years.Mepolizumab significantly reduced the number of endoscopic sinus surgeries (ESSs) (p = 0.002).The need for shortcourse oral corticosteroid (OCS) decreased significantly after mepolizumab treatment (p = 0.029).Statistically significant improvements were found in the ACT, SNOT-22, and nasal symptom scores at 6 and 12 months post-treatment when compared to baseline.No side effects were observed post-treatment.Conclusions: Mepolizumab improved nasal symptoms and reduced the need for OCS and ESS in patients with CRSwNP.However, the results obtained in the study should be confirmed with real-life studies involving larger numbers of patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI